Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

ATP Driven Pumps II: P-type Pumps01:34

ATP Driven Pumps II: P-type Pumps

6.4K
The P-type pumps are a large family of integral membrane transporter ATPases. They are divided into five major types based on substrate specificity, from I to V.
A typical P-type pump has three cytosolic domains: nucleotide-binding (N), phosphorylation (P), and activator (A) domains. These domains are connected to the membrane-spanning helices by short amino acid segments. ATP hydrolysis and covalent phosphoenzyme intermediate formation are crucial parts of the catalytic cycle. At the highly...
6.4K
ATP Driven Pumps III: V-type Pumps01:30

ATP Driven Pumps III: V-type Pumps

4.9K
V-type pumps are ATP-driven pumps found in the vacuolar membranes of plants, yeast, endosomal and lysosomal membranes of animal cells, plasma membranes of a few specialized eukaryotic cells, and some prokaryotes. They are also known as the V1Vo-ATPase, that couple ATP hydrolysis to transport protons against a concentration gradient.
The peripheral or cytosolic V1 domain with eight subunits is involved in ATP hydrolysis. The integral or transmembrane V0 domain containing at least five subunits...
4.9K
Insulin Formulations: Types and Delivery01:27

Insulin Formulations: Types and Delivery

758
Insulin preparations are categorized by their duration of action into short-acting and long-acting types. Two strategies are used to modify insulin's absorption and pharmacokinetic profile: slowing the absorption post-subcutaneous injection, or altering human insulin's amino acid sequence or protein structure. These changes retain the insulin's ability to bind to the insulin receptor, but alter its behavior in solution or after injection.
Short-acting insulins are divided into...
758
Insulin: Dosing Regimen and Adverse Effects01:16

Insulin: Dosing Regimen and Adverse Effects

788
Insulin-replacement therapy usually includes both long-acting insulin (basal) and short-acting insulin (to cater to postprandial needs). In a diverse group of type 1 diabetes patients, the average daily insulin dose is typically 0.5-0.7 units/kg body weight. However, obese patients and pubertal adolescents may need more due to insulin resistance.
The basal dose constitutes about 40%-50% of the total daily dose, with the rest as premeal insulin. The mealtime insulin dose should mirror...
788
Diabetes Mellitus: Type 2 and Gestational01:22

Diabetes Mellitus: Type 2 and Gestational

5.0K
Type 2 diabetes, characterized by insulin resistance, arises when the insulin receptors on cells lose responsiveness to insulin, diminishing the cell's capacity to take up glucose, resulting in elevated blood glucose levels. To receive a diagnosis of Type 2 diabetes, a series of blood glucose tests are necessary to assess whether the blood glucose falls within normal parameters. If the result is out of the normal range, a patient may be diagnosed as prediabetic or diabetic, depending on the...
5.0K
Diabetes Mellitus: Overview and Type I Subtype01:22

Diabetes Mellitus: Overview and Type I Subtype

5.4K
Diabetes mellitus is a chronic metabolic disorder characterized by high blood glucose levels due to inadequate insulin production, insulin resistance, or both. The condition affects millions worldwide and can significantly impact their health and quality of life.
Type 1 diabetes is an autoimmune disease in which the immune system mistakenly attacks and destroys the insulin-producing beta cells in the pancreas. As a result, the body is unable to produce sufficient insulin, and individuals with...
5.4K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Diabetes Technology Meeting 2023.

Journal of diabetes science and technology·2024
Same author

Diabetes Technology Meeting 2021.

Journal of diabetes science and technology·2022
Same author

Improving the Patient Experience With Longer Wear Infusion Sets Symposium Report.

Journal of diabetes science and technology·2022
Same author

Diabetes Technology Meeting 2020.

Journal of diabetes science and technology·2021
Same author

The Prospective Association Between Inflammation and Depressive Symptoms in Type 2 Diabetes Stratified by Sex.

Diabetes care·2019
Same author

A modelling study of the budget impact of improved glycaemic control in adults with Type 1 diabetes in the UK.

Diabetic medicine : a journal of the British Diabetic Association·2019

Related Experiment Video

Updated: Feb 6, 2026

A Protocol for Constructing a Rat Wound Model of Type 1 Diabetes
05:18

A Protocol for Constructing a Rat Wound Model of Type 1 Diabetes

Published on: February 17, 2023

5.8K

Is insulin pump therapy effective in Type 1 diabetes?

J C Pickup1

  • 1Department of Diabetes, King's College London, Guy's Hospital, London, UK.

Diabetic Medicine : a Journal of the British Diabetic Association
|August 12, 2018
PubMed
Summary

Insulin pump therapy (CSII) and multiple daily injections (MDI) offer effective Type 1 diabetes management. CSII shows particular benefit for those not reaching glycemic targets with MDI, especially in newly diagnosed children.

More Related Videos

A High-Throughput Multiplexed Screening for Type 1 Diabetes, Celiac Diseases, and COVID-19
06:46

A High-Throughput Multiplexed Screening for Type 1 Diabetes, Celiac Diseases, and COVID-19

Published on: July 5, 2022

3.3K
Regulatory T cells: Therapeutic Potential for Treating Transplant Rejection and Type I Diabetes
16:26

Regulatory T cells: Therapeutic Potential for Treating Transplant Rejection and Type I Diabetes

Published on: August 20, 2007

6.2K

Related Experiment Videos

Last Updated: Feb 6, 2026

A Protocol for Constructing a Rat Wound Model of Type 1 Diabetes
05:18

A Protocol for Constructing a Rat Wound Model of Type 1 Diabetes

Published on: February 17, 2023

5.8K
A High-Throughput Multiplexed Screening for Type 1 Diabetes, Celiac Diseases, and COVID-19
06:46

A High-Throughput Multiplexed Screening for Type 1 Diabetes, Celiac Diseases, and COVID-19

Published on: July 5, 2022

3.3K
Regulatory T cells: Therapeutic Potential for Treating Transplant Rejection and Type I Diabetes
16:26

Regulatory T cells: Therapeutic Potential for Treating Transplant Rejection and Type I Diabetes

Published on: August 20, 2007

6.2K

Area of Science:

  • Endocrinology
  • Metabolic Diseases
  • Diabetes Management

Background:

  • Uncertainty persists regarding the comparative effectiveness of insulin pump therapy (continuous subcutaneous insulin infusion, CSII) versus multiple daily insulin injections (MDI) for Type 1 diabetes.
  • Interpreting clinical trial data for CSII is challenging due to variability in patient factors and adherence.

Purpose of the Study:

  • To review the current evidence on CSII effectiveness in Type 1 diabetes.
  • To identify reasons for uncertainty in trial interpretations and suggest future research directions.

Main Methods:

  • Narrative review of existing literature on CSII versus MDI in Type 1 diabetes.
  • Analysis of factors influencing CSII effectiveness and meta-analysis limitations.

Main Results:

  • Both MDI and CSII can achieve good glycemic control in motivated individuals with structured education and healthcare support.
  • CSII offers significant advantages for patients with Type 1 diabetes struggling to reach HbA1c targets without hypoglycemia on MDI.
  • Insulin pumps are safe and effective for newly diagnosed patients, particularly children.

Conclusions:

  • CSII is a valuable option for specific Type 1 diabetes patient groups, especially those refractory to MDI.
  • Further research is needed on CSII-associated mortality and psychological interventions to improve adherence and outcomes.